Understand how bioidentical hormones are used in a clinical approach and their potential benefits for personalized health solutions.

Abstract

As Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I practice at the intersection of functional medicine, integrative chiropractic care, and advanced hormone optimization. In this educational post, I guide you through a practical, evidence-based approach to assessing and treating hormone insufficiency across the lifespan. I explain how symptoms such as anxiety, insomnia, low libido and drive, hot flashes, chronic pain, weight gain, and fibromyalgia-like tenderness often reflect insufficiencies in testosterone, estradiol, and progesterone. I then detail how I personalize therapy using testosterone and estrogen via pellets, injections, patches, and creams, when to use clomiphene to preserve fertility in men, and why micronized progesterone is central for perimenopause and endometrial protection. I also show how pellet engineering, release kinetics, and dose splitting reduce side effects such as acne, aromatization, and fluid retention.

A unique focus of my model is integrative chiropractic care—improving neuromusculoskeletal function, autonomic balance, and systemic inflammation to amplify hormone therapy outcomes. Throughout, I incorporate clinical observations from my work at https://chiropracticscientist.com/ and https://www.linkedin.com/in/dralexjimenez/. The result is a clear, actionable pathway that merges physiology with patient-centered practice.

My Integrative Framework: Where Endocrinology Meets Chiropractic Care

In my clinic, the best outcomes happen when we align biology, behavior, and biomechanics. I organize care around four pillars:

• Objective data: targeted labs; validated symptom scales such as the Menopause Rating Scale (MRS) and the Aging Male Symptoms (AMS) scale; and safety markers.
• Pharmacology matched to physiology: the right molecule, the right route, and the right interval to stabilize exposure and avoid peaks and troughs.
• Lifestyle and musculoskeletal optimization: strength, mobility, sleep, nutrition, and autonomic regulation through integrative chiropractic care.
• Iterative titration: small, frequent adjustments guided by symptoms and trough labs after steady-state is reached.

This framework respects endocrine physiology, reduces side effects, and translates hormonal signals into durable improvements in energy, mood, sleep, strength, body composition, and pain.

Understanding Hormone Insufficiency: Physiology, Patterns, and Symptoms

Many patients arrive saying they feel “off” or “unlike themselves.” The core symptom clusters I see most often include:

• Low libido, reduced arousal, decreased stamina, and motivation
• Insomnia, fragmented sleep, anxiety, and mood swings
• Hot flashes, night sweats, menstrual irregularity (perimenopause)
• Chronic pain and tenderness consistent with central sensitization
• Weight gain, especially visceral adiposity, and metabolic slowdown

Physiologically, low testosterone reduces dopaminergic tone in mesolimbic pathways, impairing motivation, reward, and sexual desire. Estradiol decline alters hypothalamic thermoregulation (driving hot flashes) and disrupts serotonergic and noradrenergic balance, amplifying anxiety and sleep disturbance. In both sexes, deficiencies in androgens and estrogens impair mitochondrial bioenergetics, reducing ATP production and raising fatigue and musculoskeletal pain burdens (see, for example, Freeman et al., 2014; Yao et al., 2017).

While SSRIs and anxiolytics can be appropriate for some, I often find that unless the hormonal drivers are addressed, symptoms only partially improve. A comprehensive, physiology-first plan—hormones, sleep, nutrition, and neuromusculoskeletal care—yields more reliable relief ([Almeida et al., 2012]; Bhasin et al., 2018).

Foundational Lab Strategy: Safety and Precision from the Start

I establish a robust baseline to guide safe, precise care:

• CBC to assess hematologic status (monitor erythrocytosis risk in androgen therapy)
• Comprehensive Metabolic Panel (CMP) for renal and hepatic function
• Thyroid panel (TSH, free T4, free T3; antibodies when indicated)
• Sex-hormone panel tailored to the patient: total and free testosterone, estradiol (sensitive assay), SHBG, DHEA-S, LH/FSH
• Metabolic and inflammation markers: fasting insulin, HbA1c, lipids, hs-CRP, vitamin D, ferritin, B12
• In men over 40 or with risk factors, PSA with shared decision-making

Thyroid sufficiency affects SHBG and metabolic rate; iron and vitamin D modulate fatigue and hair dynamics; liver function matters because steroid metabolism is hepatic. These labs help distinguish hormone-driven symptoms from other correctable contributors (Bhasin et al., 2018; [Jonklaas et al., 2014]).

FSH and Estradiol: Feedback Physiology That Guides Care

I rely on FSH as a feedback indicator of estradiol sufficiency, especially in peri- and postmenopausal women:

• When estradiol is low, FSH rises; when estradiol sufficiency returns, FSH falls.
• In a postmenopausal woman with elevated FSH, an effective estradiol therapy often lowers FSH by ~50%, typically correlating with improved hot flashes, sleep, and mood.
• In cycling women, a single estradiol value can mislead—timing and variability confound decisions—so I contextualize with cycle phase, symptoms, and, when appropriate, FSH (Stuenkel et al., 2015; NAMS Position Statements 2017/2023).

This feedback-guided approach prevents overtreatment and helps right-size estradiol to physiology while tracking safety and outcomes.

Why Route Matters: Pellets, Injections, Patches, and Creams

Different delivery routes produce distinct pharmacokinetic profiles:

• Injections (e.g., testosterone cypionate) can create pronounced peaks and troughs; splitting weekly doses into twice-weekly or microdosing subcutaneous doses flattens the curve, reducing aromatase-driven estradiol spikes and the risk of erythrocytosis (Bhasin et al., 2018; Corona et al., 2020).
• Transdermal estradiol patches provide steady delivery with favorable thrombotic and blood pressure profiles compared with oral estrogen (Vinogradova et al., 2019).
• Transdermal creams (testosterone or DHEA) have variable systemic absorption; labial (women) or scrotal (men) application improves uptake due to greater vascularity and receptor density, though serum response correlations may be inconsistent—so I monitor symptoms closely.
• Pellets offer continuous release for months, minimizing peaks and troughs and improving adherence. Proper engineering reduces early release and mid-cycle variability (Glaser & York, 2019).

My goal is hormone-mimicry—steady, physiologic exposure that stabilizes the hypothalamic-pituitary-gonadal axis and reduces symptom oscillation.

Pellet Engineering and Release Kinetics: Small Details, Big Differences

After years of experience with multiple pharmacies, I have found that pellet density, pressing direction, and excipients affect clinical outcomes:

• Horizontally pressed pellets dissolve more uniformly than some vertically pressed formats, which can release too quickly at the start, then falter mid-cycle.
• Ethylcellulose matrices slow testosterone liberation, flattening peaks that otherwise fuel acne, mood volatility, DHT surges, and aromatization to estradiol.
• Tiny amounts of triamcinolone in certain compounded pellets can reduce local inflammation and the risk of scarring at the insertion site, lowering rates of cellulitis or abscess when combined with sterile technique and good post-care.

When patients report rapid early improvements followed by a sudden dip, it often signals non-uniform release. Switching to uniform, slow-release pellets stabilizes outcomes.

Practical details I emphasize:

• Individualized dosing based on symptoms, labs, body composition, and comorbidities
• Slow-release matrices to reduce spikes and side effects
• Insertion technique to minimize tissue trauma
• Bridging for 1–2 weeks with prior modality until pellets reach stable delivery
• Monitoring reversible side effects: acne, hair changes, mood shifts, fluid retention

Testosterone Therapy in Men: Physiology, Dosing, and Safety

For men, low testosterone is associated with fatigue, low stamina, decreased muscle mass, increased body fat, depressive symptoms, and sexual dysfunction. The physiology often includes reduced Leydig cell responsiveness, higher aromatase activity in adipose tissue, and reduced insulin sensitivity (Bhasin et al., 2018).

My approach:

• Physiologic dosing first: While 200 mg/week of testosterone cypionate is common, I split doses (e.g., 100 mg twice weekly) or use subcutaneous microdosing to flatten peaks and lower aromatase substrate, often avoiding the need for aromatase inhibitors.
• Hematology matters: Flatter curves are associated with a lower risk of erythrocytosis and more stable blood pressure.
• Free testosterone and SHBG: I track free testosterone and SHBG alongside total T, aiming for symptom relief in the upper normal tertile while ensuring adequate estradiol conversion for bone, vascular, and cognitive benefits (Fink et al., 2018).

Fertility preservation:

• For younger men wishing to maintain fertility, I use clomiphene citrate to stimulate endogenous LH/FSH and testosterone production. I typically start at 25 mg daily, titrating based on symptoms and labs; the effect attenuates with age as LH responsiveness wanes (Taylor & Levine, 2010).

Clinical observation:

• Men transitioning from a single weekly 200 mg dose to 100 mg twice weekly frequently report fewer mood swings and less water retention within 2–3 weeks. Microdosed subcutaneous regimens often stabilize sleep architecture and morning readiness.

Testosterone in Women: Restoring Drive, Clarity, and Musculoskeletal Integrity

Women benefit from carefully titrated testosterone, especially for low libido, fatigue, cognitive fog, and sarcopenia risk. Androgen sensitivity in female tissues is high; small titrations can drive meaningful improvements:

• I often use 10–50 mg per week (in divided doses) depending on menopausal status and symptom burden, or consider daily microdosing for steadier exposure.
• Transdermal options (including labial application) can help with local tissue health and lubrication; pellets or subcutaneous microdosing provide broader systemic steadiness with fewer peaks.
• I monitor for virilization (acne, hirsutism, voice changes) and adjust dosing or route as needed. Slow-release pellet formulations with ethylcellulose are especially helpful to minimize DHT and aromatase.

Evidence supports androgen therapy for women with specific indications, such as hypoactive sexual desire disorder, when dosed judiciously and monitored for safety and efficacy (Davis et al., 2019).

---

Modulating Women’s Hormones-Video

---

Progesterone in Perimenopause and Postmenopause: Calming the System and Protecting the Endometrium

From the mid-40s onward, luteal insufficiency is common. Women present with heavy, clotty bleeding, short cycles, breast tenderness, irritability, and bedtime restlessness—classic progesterone deficiency signs. My go-to:

• Oral micronized progesterone 100 mg nightly in perimenopause; titrate based on bleeding, sleep, and anxiety. For severe symptoms, I increase frequency or dose with careful monitoring.
• For postmenopausal women on systemic estradiol with a uterus, 200 mg nightly provides robust endometrial protection and improves sleep via GABA-A receptor. If morning grogginess arises, dose earlier or reduce the dose.
• I avoid relying on progesterone creams for endometrial protection due to inconsistent endometrial exposure; oral micronized progesterone has the strongest safety data (Stute et al., 2020).

The result is calmer sleep, improved mood stability, and safer integration of estrogen therapy (de Villiers et al., 2020).

Estrogen Therapies: Transdermal First for Safety and Control

For systemic estrogen therapy, I prefer transdermal 17-beta estradiol:

• Avoids first-pass hepatic metabolism that increases clotting factors and triglycerides seen with oral estradiol.
• Provides steadier vasomotor relief with a better thrombotic profile (The NAMS 2022 Position Statement, 2022; Vinogradova et al., 2019).

For local symptoms such as genitourinary syndrome of menopause, vaginal estradiol or DHEA creams provide local benefits with minimal systemic absorption.

Perimenopause nuance:

• I often use a low, steady estradiol baseline—in pellet form, this can be a 6 mg range dose—to stabilize lows without overshooting endogenous highs that still occur in perimenopause. This approach reduces hot flashes, mood lability, and menstrual migraines without provoking fluid retention and breakthrough bleeding associated with higher, postmenopausal-style dosing.

Managing Aromatization, DHT, and Common Side Effects

When testosterone spikes, conversion to estradiol (via aromatase) and DHT (via 5-alpha-reductase) accelerates, leading to acne, fluid retention, gynecomastia in men, and hair changes in women. My control strategies:

• Prefer steady-state delivery: pellets with ethylcellulose matrices, dose-splitting for injections, or microdosing to flatten peaks.
• Body composition: Reduce visceral fat to reduce aromatase activity.
• Nutrition: limit ultra-processed carbohydrates and alcohol that upregulate aromatase and worsen fluid retention.
• Judicious, short-term aromatase inhibitors or 5-alpha-reductase modulators only when clearly indicated by labs and symptoms—overuse can worsen lipids, joints, and bone (Bhasin et al., 2018).

This “mimic physiology, avoid spikes” philosophy minimizes side effects while preserving benefits.

Practical Dosing and Monitoring: A Data-Driven, Symptom-First Workflow

I standardize the intake-to-treatment journey to ensure clarity:

• Baseline: labs and validated symptom scales (MRS/AMS) before first consult.
• Shared decision-making: pellets vs. injections vs. patches/creams based on goals, preferences, and safety.
• Initiation:

• • Men declining pellets: start testosterone cypionate with split dosing (e.g., 100 mg twice weekly) or subcutaneous microdosing; teach technique and site care.
  • Perimenopausal women: start 100 mg oral micronized progesterone nightly; add transdermal estradiol if hot flashes or sleep remain problematic.
  • Postmenopausal women: transdermal estradiol with 200 mg oral micronized progesterone nightly if uterus is present.

• Bridging: maintain prior testosterone modality for ~2 weeks after pellet placement; stop estrogen patches 3–5 days after estradiol pellets to avoid troughs.
• Follow-up: reassess MRS/AMS at 3 weeks and 6–8 weeks; draw trough labs after 4–5 consistent doses or at 5–6 weeks post-pellet.
• Iterate: adjust dose or interval, consider boosts for persistent symptoms, and integrate lifestyle and chiropractic supports.

Safety monitoring includes hematocrit/hemoglobin, blood pressure, lipids, liver function, PSA (when appropriate), and endometrial status as indicated.

Integrative Chiropractic Care: Enhancing Endocrine Outcomes

Hormone optimization is amplified when the neuromusculoskeletal and autonomic environment is optimized. In my practice, integrative chiropractic care accelerates recovery and deepens results:

• Autonomic regulation: Pain and segmental dysfunction increase sympathetic tone, elevating cortisol and catecholamines, which dampen GnRH pulsatility and downstream sex hormone secretion. Evidence-informed spinal manipulation and soft-tissue work rebalance autonomic tone, improving sleep and stress resilience (Pickar & Bolton, 2012; Budgell, 2005).
• Pain reduction and central sensitization: Reducing nociceptive input downshifts hyperalgesic circuits. When combined with hormone-driven anabolic repair, patients often see marked reductions in fibromyalgia-like pain.
• Biomechanical efficiency: Optimized alignment improves force transmission and proprioceptive input, enabling progressive resistance training—the single most potent non-pharmacologic tool for improving insulin sensitivity, osteogenesis, and lean mass under an anabolic milieu (Kraemer & Ratamess, 2005; Kjaer, 2004).
• Neuroimmune modulation: Manual therapy and exercise reduce inflammatory cytokine levels; lower hs-CRP levels correlate with better hormone responsiveness ([Pedersen & Saltin, 2019]).

Clinical observations (shared at https://chiropracticscientist.com/ and on my profile at https://www.linkedin.com/in/dralexjimenez/):

• Patients receiving combined pellet therapy and a progressive chiropractic plan report faster improvements in sleep quality, mood stability, strength, and pain. Those using subcutaneous microdosing plus chiropractic care often note steadier day-to-day energy and training tolerance.

Special Populations and Considerations

• Menstrual migraines: Often triggered by estrogen withdrawal. A low, steady estradiol baseline prevents precipitous drops and reduces migraine frequency and severity. Testosterone optimization can also improve sleep and pain thresholds, but estradiol stabilization is key for classic withdrawal migraines (MacGregor, 2017; Calhoun, 2018).
• Breastfeeding: Limited data suggest minimal testosterone transfer into breast milk with physiologic dosing; I discuss the evidence constraints and engage in shared decision-making ([ABM, 2020]).
• Pregnancy: Do not initiate or continue pellets during pregnancy; if conception occurs after insertion, we pause further therapy and monitor.
• Psychotropics and sensitivities: In patients on SSRIs/stimulants or with medication sensitivities, I start at lower hormone doses and titrate slowly, coordinating care with prescribers.
• SSRI weaning: After hormone balance is restored, some patients choose to taper SSRIs under their prescriber’s guidance to improve libido and weight; I use gradual tapering schedules and close monitoring ([APA, 2010]; [Corona et al., 2010]).

Case-Style Narratives: Translating Physiology into Outcomes

• A 36-year-old man declining pellets started testosterone cypionate 200 mg/week, split into 100 mg twice weekly subcutaneously. At the fifth dose trough, hematocrit remained stable, estradiol was physiologic, and AMS scores improved. With chiropractic adjustments optimizing hip hinge mechanics, he progressed in strength training without overuse injuries and reported steadier energy and sleep—without the need for an aromatase inhibitor.
• A 48-year-old perimenopausal woman with heavy, clotty cycles, night anxiety, and early awakenings began 100 mg oral micronized progesterone nightly, plus 25 mg sublingual PRN for evening anxiety. At 3 weeks, her sleep deepened, and bleeding stabilized. We added a physiologic transdermal estradiol dose for residual hot flashes. With integrative chiropractic care focusing on thoracic mobility, diaphragmatic breathing, and posterior chain strength, she showed improved HRV and mood within 8 weeks.
• A postmenopausal woman with fibromyalgia-like pain and low motivation initiated pellet-based testosterone and estradiol engineered for slow release. Within one cycle, she noted improved sleep continuity, strength, and reduced widespread tenderness. Graded exercise under chiropractic guidance lowered central sensitization, and an anti-inflammatory diet sustained the gains.

These patients illustrate how steady hormone exposure combined with biomechanical and autonomic optimization creates durable change.

Putting It All Together: A Systems-Based, Evidence-Aligned Care Model

• Assess root drivers: Use comprehensive labs and validated scales; consider thyroid, iron, vitamin D, and inflammation.
• Favor steady-state delivery: Pellets (well-engineered), estradiol patches, or injection microdosing to avoid peaks and troughs.
• Protect endometrium with progesterone: Use oral micronized progesterone; avoid relying on creams for systemic protection.
• Preserve male fertility when desired: Consider clomiphene citrate for endogenous stimulation.
• Manage aromatization and DHT physiologically: Steady delivery, body composition optimization, and nutrition; reserve AIs/5-alpha-reductase agents for clear indications.
• Leverage integrative chiropractic care: Align structure and autonomics to enhance endocrine expression and training capacity.
• Iterative titration: Let symptoms and trough labs guide small dose adjustments; use “boosts” thoughtfully.
• Layer therapies: Stabilize hormones first, then consider DHEA, thyroid optimization, or GLP-1 agonists as indicated.

This systems approach yields clarity, stability, and vitality—rooted in physiology and refined in practice.

References

• Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Wu, F. C. W. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism.
• Budgell, B. (2005). Reflex effects of subluxation: The autonomic nervous system. Journal of Manipulative and Physiological Therapeutics.
• Calhoun, A. H. (2018). Hormonal contraceptives and migraine headache. Cephalalgia.
• Corona, G., Goulis, D. G., Huhtaniemi, I., Zitzmann, M., Toppari, J., Forti, G., & Maggi, M. (2020). European Academy of Andrology guidelines on investigation, treatment, and monitoring of functional hypogonadism in males. Andrology.
• Corona, G., Ricca, V., Bandini, E., Mannucci, E., Lotti, F., Boddi, V., et al. (2010). Selective serotonin reuptake inhibitor-induced sexual dysfunction. Journal of Sexual Medicine.
• Davis, S. R., Wahlin-Jacobsen, S., & Sassarini, J. (2019). Androgen therapy in women: A concise review. Climacteric.
• de Villiers, T. J., Hall, J. E., Pinkerton, J. V., Pérez, S. C., Rees, M., Yang, C., & Pierroz, D. D. (2020). Revised global consensus statement on menopausal hormone therapy. Climacteric.
• Fink, J., Matsumoto, A. M., & Tamler, R. (2018). Estradiol in men: Clinical implications. Therapeutic Advances in Endocrinology and Metabolism.
• Freeman, E. W., Sammel, M. D., Lin, H., & Gracia, C. R. (2014). Obesity and reproductive hormones during the menopausal transition. Menopause.
• Glaser, R., & York, A. E. (2019). Subcutaneous hormone pellet therapy: A review of safety and efficacy. International Journal of Pharmaceutical Compounding.
• Heinemann, L. A. J., Potthoff, P., & Schneider, H. P. G. (2003). International versions of the Menopause Rating Scale (MRS). Health and Quality of Life Outcomes.
• Kjaer, M. (2004). Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiological Reviews.
• Kraemer, W. J., & Ratamess, N. A. (2005). Hormonal responses and adaptations to resistance exercise and training. Sports Medicine.
• MacGregor, E. A. (2017). Estrogen and attacks of migraine with and without aura. Therapeutic Advances in Neurological Disorders.
• Pickar, J. G., & Bolton, P. S. (2012). Spinal manipulation and somatosensory processing. Journal of Electromyography and Kinesiology.
• Rosner, W., Vesper, H., & Endocrine Society. (2013). Toward excellence in testosterone testing: A consensus statement. Journal of Clinical Endocrinology & Metabolism.
• Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism.
• Stute, P., Wildt, L., & Neulen, J. (2020). The impact of micronized progesterone on the endometrium: A systematic review. Climacteric.
• Taylor, F., & Levine, L. (2010). Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: Efficacy and safety. Journal of Urology.
• The NAMS 2022 Position Statement. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause.
• Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019). Use of menopausal hormone therapy and risk of venous thromboembolism. BMJ.
• Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.

Additional resources and my clinical observations:

• https://chiropracticscientist.com/
• https://www.linkedin.com/in/dralexjimenez/

SEO tags: hormone pellets, testosterone therapy men, androgen therapy women, estradiol patch safety, oral micronized progesterone, clomiphene fertility preservation, aromatase DHT management, ethylcellulose slow-release pellet, triamcinolone pellet insertion, subcutaneous testosterone microdosing, integrative chiropractic care hormones, autonomic regulation HRV, perimenopause estradiol low dose, menstrual migraine estrogen stabilization, SHBG free testosterone, MRS AMS symptom scales, trough labs timing, fibromyalgia hormone optimization, neuromusculoskeletal alignment and hormones